Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.54 |
| ▸ | JAK3 | P52333 | 2/20 | 0.53 |
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 3/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.47 |
| ▸ | AURKA | O14965 | 3/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.45 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18386697 | 0.94 | SUV39H2 (0.50) | MAP4K4JAK3BTKPDE10AIRAK4 | |
| SCHEMBL30267297 | 0.90 | JAK3 (0.51) | MAP4K4JAK3BTKRETPDE10A | |
| SCHEMBL31205530 | 0.84 | IRAK4 (0.48) | PDE10AIRAK4SUV39H2 | |
| SCHEMBL31236411 | 0.84 | IRAK4 (0.48) | IRAK4 | |
| SCHEMBL15280693 | 0.83 | SUV39H2 (0.56) | MAP4K4JAK3BTKPDE10ASUV39H2 | |
| SCHEMBL31441616 | 0.83 | SUV39H2 (0.56) | MAP4K4JAK3BTKPDE10ASUV39H2 | |
| SCHEMBL21996805 | 0.83 | IRAK4 (0.49) | MAP4K4IRAK4 | |
| SCHEMBL30267215 | 0.82 | MAP4K4 (0.57) | MAP4K4JAK3BTKRETPDE10A | |
| SCHEMBL30267076 | 0.82 | MAP4K4 (0.57) | MAP4K4JAK3BTKRETPDE10A | |
| SCHEMBL30267391 | 0.80 | IRAK4 (0.58) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180208605-A1 | Substituted Aza Compounds as IRAK-4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208605-A1 | Substituted Aza Compounds as IRAK-4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-07-26 | — | — | US | disclosed |
| WO-2017009806-A1 | SUBSTITUTED AZA COMPOUNDS AS IRAK-4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208605-A1 | Substituted Aza Compounds as IRAK-4 Inhibitors | IRAK4, IRAK2, IRAK1 | MAP4K4 256/4885JAK3 145/4885BTK 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.